Get started
Author

Gianluca Quintini

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2
2021 · Peter G. Kremsner, Philipp Mann, et al. · Wiener klinische Wochenschrift · 203
PDF
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
2021 · Peter G Kremsner, Rodolfo Andrés Ahuad Guerrero, et al. · The Lancet Infectious Diseases · 182
PDF
The sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleen
2011 · Matthias Schröder, Cornelia Richter, et al. · Molecular Immunology · 38
Synthesis and biological evaluation of novel (4 or 5-aryl)pyrazolyl-indoles as inhibitors of interleukin-2 inducible T-cell kinase (ITK)
2010 · Avdhoot D. Velankar, Gianluca Quintini, et al. · Bioorganic & Medicinal Chemistry · 36
Multi-analyte profiling of inflammatory mediators in COPD sputum – The effects of processing
2014 · Frauke Pedersen, Olaf Holz, et al. · Cytokine · 23
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study
2022 · Xavier Sáez-Llorens, Claudio Lanata, et al. · Vaccine X · 21
Identification of potent ITK inhibitors through focused compound library design including structural information
2010 · Matthias Herdemann, Isabelle Heit, et al. · Bioorganic & Medicinal Chemistry Letters · 19
The 5′-flanking region of humanCD24 gene has cell-type-specific promoter activity in small-cell lung cancer
1998 · Maria K. Pass, Gianluca Quintini, et al. · International Journal of Cancer · 18
PDF
Role of Amino-Terminal Histone Domains in Chromatin Replication
1996 · Gianluca Quintini, Kai Treuner, et al. · Molecular and Cellular Biology · 18
A phase I dose-escalation and expansion study of intratumoral CV8102 as single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors.
2020 · Thomas Eigentler, Franz G Bauernfeind, et al. · Journal of Clinical Oncology · 14
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
2025 · Thomas Eigentler, Ioannis Thomas, et al. · Journal for ImmunoTherapy of Cancer · 11
PDF
A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant
2022 · Olaf-Oliver Wolz, Sarah-Katharina Kays, et al. · Vaccines · 9
PDF
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity
2024 · Olaf-Oliver Wolz, Dominik Vahrenhorst, et al. · Vaccines · 3
PDF
Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]
2023 · Xavier Sáez-Llorens, Claudio Lanata, et al. · Vaccine X · 2
A phase 3, randomised, observer-blinded, placebo controlled-trial evaluating the safety and immunogenicity of investigational SARS-CoV-2 mRNA vaccine CVnCoV in adult healthcare workers in Mainz (Germany)
2024 · Frank Kowalzik, Daniel Teschner, et al. · Vaccine X · 1
784 Immune profiling of patients with advanced melanoma intratumorally treated with CV8102 as a single-agent or in combination with anti-PD-1 antibodies – results of a phase I trial expansion
2022 · Marina Gonzalez, Peter Wengenmayer, et al. · Journal for ImmunoTherapy of Cancer
PDF
473 Immune profiling of patients with advanced solid tumors treated with intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in phase I clinical trial
2021 · Paula Codó, Thomas Eigentler, et al. · Journal for ImmunoTherapy of Cancer
PDF
Multi-analyte profiling of inflammatory markers in COPD sputum
2014 · Frauke Pedersen, Gereon Lauer, et al. · European Respiratory Journal
Works count: 18
Citation count: 598
H-index: 11
I10-index: 11
Year
Topic
Type